Characterization of purified dog mastocytoma cells. Autonomic membrane receptors and pharmacologic modulation of histamine release.
There is conflicting evidence as to which autonomic receptors mast cells possess and whether the receptors are capable of modulating mediator release. We have studied dog mastocytoma cells because they are available in large numbers in a relatively pure form, unlike normal dog mast cells. Mastocytoma nodules from a dog were excised and disaggregated with collagenase to provide a cell suspension of mastocytoma cells of greater than 92% purity. The presence of autonomic receptors was assessed by both radioligand binding assays and by evaluating pharmacologic modulation of mediator release. In the radioligand binding assays, beta-adrenergic receptors were estimated by [3H]dihydroalprenolol binding, alpha-adrenergic receptors by [3H]prazosin binding and cholinergic receptors by [3H]quinuclidinyl benzilate binding. Nonspecific binding was determined in each case by incubation in the presence of the specific antagonists propranolol, phentolamine, and atropine, respectively. The effect of autonomic agonists on immunologic and nonimmunologic histamine release was examined, using the beta-adrenergic agonists isoproterenol and terbutaline, the alpha-adrenergic agonist phenylephrine with and without propranolol, and the cholinergic agonist acetylcholine. Dose-response curves were constructed both for the autonomic agonists and the histamine-releasing agents. Results from the radioligand binding and the pharmacologic studies were concordant. These dog mastocytoma cells had a high density of beta-receptors (21,500 +/- 3,300; mean +/- SE beta-receptors/cell, n=5) of which the predominant subtype appeared to be beta2. No evidence was found for the presence of alpha-adrenergic or cholinergic receptors either by direct receptor binding or by their actions on histamine release.
M J
MJ
Phillips
P J
PJ
Barnes
W M
WM
Gold
D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D000242:Cyclic AMP / Q000032:analysis; D004082:Dihydroalprenolol / Q000378:metabolism; D004285:Dogs; D006636:Histamine Release / Q000187:drug effects*; D066298:In Vitro Techniques; D007545:Isoproterenol / Q000494:pharmacology; D012515:Mast-Cell Sarcoma / Q000032:analysis* / Q000378:metabolism; D010656:Phenylephrine / Q000494:pharmacology; D011224:Prazosin / Q000378:metabolism; D011433:Propranolol / Q000494:pharmacology; D011813:Quinuclidinyl Benzilate / Q000378:metabolism; D011869:Radioligand Assay; D011942:Receptors, Adrenergic, alpha / Q000032:analysis*; D011943:Receptors, Adrenergic, beta / Q000032:analysis*; D011950:Receptors, Cholinergic / Q000032:analysis*; D013726:Terbutaline / Q000494:pharmacology
D011942:Receptors, Adrenergic, alpha; D011943:Receptors, Adrenergic, beta; D011950:Receptors, Cholinergic; D010656:Phenylephrine; D004082:Dihydroalprenolol; D011813:Quinuclidinyl Benzilate; D011433:Propranolol; D000242:Cyclic AMP; D007545:Isoproterenol; D013726:Terbutaline; D000109:Acetylcholine; D011224:Prazosin